RecruitingNot Applicable

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

United States5,950 participantsStarted 1998-03-12

Plain-language summary

Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI....

Who can participate

Age range

2 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

Individuals whose co-morbidities preclude surgical intervention.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Investigate quality of life in men who have prostate cancer.

Timeframe: on-going

Investigate molecular genetic basis of urologic malignancies

Timeframe: on-going

Investigate cellular/biochemical response to existing and novel therapeutic agents.

Timeframe: on-going

Examine protein expression and bioimmunoassays investigating potential genetic markers.

Timeframe: on-going

Determine the molecular genetic differences between normal and tumorigenic tissues.

Timeframe: on-going

Collection of benign and malignant tissue from individuals with rare inherited conditions associated with an increased risk for kidney cancer.

Timeframe: on-going

Collection of benign and malignant tissue from individuals with known or suspected cancer.

Timeframe: on-going

Trial details

NCT IDNCT00026884

SponsorNational Cancer Institute (NCI)

Sponsor typeNIH

Study typeOBSERVATIONAL

Contact for this trial

Deborah A Nielsen, R.N.

(240) 760-6247 deborah.nielsen@nih.gov

View on ClinicalTrials.gov More Malignant Neoplasms trials

Plain-language summary

What they're measuring

Investigate quality of life in men who have prostate cancer.

Timeframe: on-going

Investigate molecular genetic basis of urologic malignancies

Timeframe: on-going

Investigate cellular/biochemical response to existing and novel therapeutic agents.

Timeframe: on-going

Examine protein expression and bioimmunoassays investigating potential genetic markers.

Timeframe: on-going

Determine the molecular genetic differences between normal and tumorigenic tissues.

Timeframe: on-going

Collection of benign and malignant tissue from individuals with rare inherited conditions associated with an increased risk for kidney cancer.

Timeframe: on-going

Collection of benign and malignant tissue from individuals with known or suspected cancer.

Timeframe: on-going